Incyte International Locations

Developing the Next Generation of Dermatology Treatments

Incyte’s science-first approach and heritage in immunology has formed the foundation of our company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.

NAVIGATE TO

Approved Therapies Resources

Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa.

Research has shown that the JAK-STAT pathway mediates the cellular effects of cytokines involved in the pathogenesis of many immune-mediated dermatologic conditions. We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis.

Disease Areas of Interest

Atopic dermatitis

Atopic dermatitis (AD)—the most common type of eczema—is an immune-mediated skin condition that causes irritation and itch.

Learn more about atopic dermatitis here

Open

Atopic dermatitis (AD) is a common chronic disease characterized by inflammation of the skin. Signs and symptoms of AD include irritated and itchy skin that can cause red lesions that may ooze and crust.¹ Patients with AD are also more susceptible to bacterial, viral and fungal infections.² The clinical signs and symptoms of the disease can have a profound impact on a patient’s quality of life.^3-8

Vitiligo

Vitiligo is a condition that causes the skin to lose its pigment cells (melanocytes), often resulting in discolored patches of the skin.

Learn more about vitiligo here

Open

Vitiligo is a chronic autoimmune disease characterized by depigmentation of skin that results from the loss of pigment-producing cells known as melanocytes. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo. It affects approximately 0.5% to 2.0% of the population globally.⁹ In the United States, more than 1.5 million people are diagnosed with vitiligo.¹⁰ The overall prevalence of the condition is estimated to be approximately 2–3 million,¹¹ with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo.¹² Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 30.¹³ Vitiligo is associated with quality-of-life impairments^14,15and patients are at an increased risk for comorbidities and mental health disorders, including depression.^16,17

Hidradenitis suppurativa

Red, painful lumps can develop under the skin for many reasons—including a condition called hidradenitis suppurativa.

Learn more about hidradenitis suppurativa here

Open

Hidradenitis suppurativa, also known as acne inversa, is an inflammatory skin condition that causes painful bumps to form in the armpit, groin, breast and anal regions of the body.¹⁴ The condition typically begins during puberty and is often most active between the ages of 20 and 40 years. Some of the bumps can eventually lead to disfiguring scars. It has a significant impact on daily life and can be debilitating for some patients.¹⁴

Approved Therapies

United States

Learn more about Opzelura^TM
(ruxolitinib) cream

For Patients For HCPs

Medical Information

Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you are seeking medical information on our products, or wish to meet with a Medical Science Liaison, please visit IncyteMI.com.

To report a possible Adverse Event or Product Complaint related to an Incyte product, contact Incyte Medical Information by calling 1-855-4-MEDINFO (1-855-463-3463).

Resources

United States

FOR PATIENTS

Start from Scratch

This site is a resource for those living with atopic dermatitis (AD). It was informed by people with AD, as well as advocates, and aims to provide information about the science behind AD and help empower patients to have more productive conversations with their dermatologists.

Learn More with Start from Scratch

IncyteCARES

Through IncyteCARES—a patient support and assistance program for eligible patients prescribed Jakafi, Pemazyre, or Opzelura—we strive to implement initiatives that support patients and remove barriers to accessing these medicines in the U.S. Our team can help patients with understanding their insurance coverage, exploring financial assistance options and providing as-needed support.

Learn About IncyteCARES

FOR HEALTHCARE PROFESSIONALS

Medical Information

To report a possible Adverse Event or Product Complaint related to an Incyte product, contact Incyte Medical Information by calling 1-855-4-MEDINFO (1-855-463-3463).

References